YS Biopharma Co Ltd (NASDAQ: YS) has seen a rise in its stock price by 18.75 in relation to its previous close of 0.80. However, the company has experienced a 26.67% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-19 that YS Biopharma Co., Ltd. (NASDAQ:YS ) Q3 2024 Earnings Conference Call April 19, 2024 8:00 AM ET Company Participants Alyssa Li – Director, Investor Relations David Shao – President & Chief Executive Officer Zenaida Mojares – Chief Medical Officer Brenda Wu – Chief Financial Officer Conference Call Participants Hunter Diamond – Diamond Equity Research Operator Ladies and gentlemen, thank you for standing by and welcome to YS Biopharma’s Earnings Call for the First Nine Months of Fiscal Year 2024.
Is It Worth Investing in YS Biopharma Co Ltd (NASDAQ: YS) Right Now?
Company’s 36-month beta value is 0.56.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for YS is 17.94M, and currently, short sellers hold a 0.53% ratio of that floaft. The average trading volume of YS on May 09, 2024 was 182.92K shares.
YS’s Market Performance
YS’s stock has seen a 26.67% increase for the week, with a 11.76% rise in the past month and a 136.91% gain in the past quarter. The volatility ratio for the week is 9.80%, and the volatility levels for the past 30 days are at 11.79% for YS Biopharma Co Ltd The simple moving average for the past 20 days is 17.91% for YS’s stock, with a 33.02% simple moving average for the past 200 days.
YS Trading at 32.27% from the 50-Day Moving Average
After a stumble in the market that brought YS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.63% of loss for the given period.
Volatility was left at 11.79%, however, over the last 30 days, the volatility rate increased by 9.80%, as shares surge +5.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +137.56% upper at present.
During the last 5 trading sessions, YS rose by +26.67%, which changed the moving average for the period of 200-days by -33.10% in comparison to the 20-day moving average, which settled at $0.8082. In addition, YS Biopharma Co Ltd saw 85.91% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for YS
Current profitability levels for the company are sitting at:
- -0.51 for the present operating margin
- 0.8 for the gross margin
The net margin for YS Biopharma Co Ltd stands at -0.49. The total capital return value is set at -0.5.
The debt to equity ratio resting at 1.17. The interest coverage ratio of the stock is -20.97.
Currently, EBITDA for the company is -76.82 million with net debt to EBITDA at -1.18. When we switch over and look at the enterprise to sales, we see a ratio of 2.62. The receivables turnover for the company is 1.54for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.94.
Conclusion
In a nutshell, YS Biopharma Co Ltd (YS) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
